CSIMarket
 
Zai Lab Limited  (NASDAQ: ZLAB)
Other Ticker:  
 
 
Price: $27.5300 $-0.28 -1.007%
Day's High: $28.0339 Week Perf: 0.55 %
Day's Low: $ 27.09 30 Day Perf: 6.66 %
Volume (M): 495 52 Wk High: $ 36.60
Volume (M$): $ 13,638 52 Wk Avg: $21.51
Open: $27.84 52 Wk Low: $13.48



 Market Capitalization (Millions $) 27,026
 Shares Outstanding (Millions) 982
 Employees 678
 Revenues (TTM) (Millions $) 356
 Net Income (TTM) (Millions $) -271
 Cash Flow (TTM) (Millions $) -73
 Capital Exp. (TTM) (Millions $) 45

Zai Lab Limited
Zai Lab Limited (ZLAB) is a Chinese biopharmaceutical company that focuses on discovering, developing, and commercializing innovative medicines for the treatment of oncology, autoimmune, and infectious diseases. The company was founded in 2014 by Dr. Samantha Du, an experienced pharmaceutical executive with a proven track record of successful drug development and commercialization.

Zai Lab has a broad pipeline of product candidates that target a range of diseases, including several late-stage clinical programs that are approaching commercialization. The company's lead product candidate is Zejula, a PARP inhibitor that is currently in Phase III clinical trials for the treatment of ovarian cancer. The company is also developing other oncology drugs, including novel kinase inhibitors and immuno-oncology therapies.

In addition to its oncology pipeline, Zai Lab has several product candidates in development for autoimmune diseases, such as atopic dermatitis and rheumatoid arthritis, as well as infectious diseases, such as COVID-19 and hepatitis B.

Zai Lab has a strong track record of partnership and collaboration with leading biopharmaceutical companies, including Sanofi, Bristol Myers Squibb, and GlaxoSmithKline. These partnerships have provided Zai Lab with access to key technologies and expertise, and have helped to accelerate the development of its product candidates.

The company aims to become a leading biopharmaceutical company in China, and has invested heavily in building a world-class research and development infrastructure. This includes state-of-the-art laboratories and manufacturing facilities, as well as a team of experienced scientists and researchers.

Zai Lab has a strong financial position, with a market capitalization of over $18 billion as of June 202 The company has a solid balance sheet, with over $1 billion in cash, cash equivalents, and short-term investments as of March 31, 202

In summary, Zai Lab Limited is a rapidly growing Chinese biopharmaceutical company with a portfolio of innovative product candidates in oncology, autoimmune diseases, and infectious diseases. The company has established strong partnerships with leading biopharmaceutical companies and has invested heavily in research and development infrastructure. With a strong financial position and a growing pipeline of product candidates, Zai Lab is well-positioned for continued success in the biopharmaceutical industry.


   Company Address: 4560 Jinke Road Shanghai 201210
   Company Phone Number: 6163 2588   Stock Exchange / Ticker: NASDAQ ZLAB


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY   -5.17%    
LLY        8.38% 
PFE   -1.76%    
REGN        6.47% 
TEVA   -3%    
VTRS   -2.81%    
• View Complete Report
   



Business Update

Promising Developments in Pancreatic Cancer Treatment Insights from the Phase 3 PANOVA-3 Trial

Published Mon, Dec 2 2024 2:47 PM UTC

The realm of pancreatic cancer treatment has witnessed a promising breakthrough with the recent announcement of positive topline results from the Phase 3 PANOVA-3 clinical trial. This trial is a collaborative venture between Zai Lab Limited and Novocure, two leading entities in the pharmaceutical landscape. The study explores the efficacy of Tumor Treating Fields (TTFields)...

Business Update

Zai Lab Secures Inclusion of AUGTYRO in China?s National Reimbursement Drug List, Announces Upcoming Presenta...

Published Thu, Nov 28 2024 4:47 AM UTC

In a significant advancement for both healthcare access and cancer treatment in China, Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) announced the inclusion of AUGTYRO (repotrectinib) in the recently updated National Reimbursement Drug List (NRDL). The announcement, made in Shanghai and Cambridge, marks a crucial step in improving treatment options for adult patients with local...

Business Update

Zai Lab Announces Pricing of Public Offering of American Depositary Shares

Published Fri, Nov 15 2024 1:56 AM UTC

Zai Lab Limited Prices Public Offering Amidst Strong Revenue Growth and Competitive LandscapeIn a significant move to bolster its financial standing, Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a leading biopharmaceutical company based in Shanghai and Cambridge, has announced the pricing of its underwritten public offering of American depositary shares (ADSs). The offering ...

Business Update

Advancements in Oncology and Infectious Disease Zai Labs Pioneering Therapies and Their Clinical Potential

Published Tue, Aug 27 2024 1:52 PM UTC

Abstract Zai Lab Limited, a prominent biopharmaceutical company, is poised to make significant contributions to the treatment landscape in oncology and infectious diseases. This article summarizes key developments from Zai Lab, including the presentation of preliminary data from the Phase 1 trial of ZL-1218, an investigational anti-CCR8 antibody for advanced solid tumors, in...

Business Update

Multifaceted Advancements in Oncology and Bacteriology Signal a New Era of Treatment Potential by Zai Lab

Published Tue, Jul 16 2024 5:54 AM UTC

In recent years, Zai Lab Limited has consistently positioned itself at the forefront of medical advancements, championing the development of innovative treatments in oncology and bacteriology. This article delves into the latest breakthroughs that underscore Zai Lab?s commitment to leveraging cutting-edge research and collaborative efforts to address complex medical challeng...







Zai Lab Limited's Segments
ZEJULA    47.16 % of total Revenue
OPTUNE    7.54 % of total Revenue
QINLOCK    8.45 % of total Revenue
NUZYRA    9.78 % of total Revenue
VYVGART    26.66 % of total Revenue





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com